Kidney dosimetry during ¹⁷⁷Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance

References

• Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29:2416–2423.
   PubMed Web of Science ®Google Scholar
• Bodei L, Cremonesi M, Grana CM, et al. Peptide receptor radionuclide therapy with (1)Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125–2135.
   PubMed Web of Science ®Google Scholar
• Gabriel M, Andergassen U, Putzer D, et al. Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients. Q J Nucl Med Mol Imaging. 2010;54:92–99.
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–2130.
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754–2762.
   PubMed Web of Science ®Google Scholar
• Williams LE, DeNardo GL, Meredith RF. Targeted radionuclide therapy. Med Phys. 2008;35:3062–3068.
   PubMed Web of Science ®Google Scholar
• Bodei L, Cremonesi M, Ferrari M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35:1847–1856
   PubMed Web of Science ®Google Scholar
• Valkema R, Pauwels SA, Kvols LK, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med. 2005;46:83S–91S.
   PubMed Web of Science ®Google Scholar
• Bodei L, Cremonesi M, Grana C, et al. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31:1038–1046.
   PubMed Web of Science ®Google Scholar
• Moll S, Nickeleit V, Mueller-Brand J, et al. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis. 2001;37:847–851.
   PubMed Web of Science ®Google Scholar
• Ilan E, Sandstrom M, Wassberg C, et al. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE. J Nucl Med. 2015;56:177–182.
   PubMed Web of Science ®Google Scholar
• Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–122.
   PubMed Web of Science ®Google Scholar
• Konijnenberg MW. Is the renal dosimetry for [90Y-DOTA0,Tyr3]octreotide accurate enough to predict thresholds for individual patients? Cancer Biother Radiopharm. 2003;18:619–625.
   PubMed Web of Science ®Google Scholar
• Konijnenberg M, Melis M, Valkema R, et al. Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. J Nucl Med. 2007;48:134–142.
   PubMed Web of Science ®Google Scholar
• Barone R, Borson-Chazot F, Valkema R, et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005;46:99S–106S.
   PubMed Web of Science ®Google Scholar
• Sabet A, Ezziddin K, Pape UF, et al. Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate. Eur J Nucl Med Mol Imaging. 2014;41:505–510.
   PubMed Web of Science ®Google Scholar
• Hindorf C, Glatting G, Chiesa C, et al. EANM dosimetry committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging. 2010;37:1238–1250.
   PubMed Web of Science ®Google Scholar
• Ljungberg M, Sjogreen-Gleisner K. The accuracy of absorbed dose estimates in tumours determined by quantitative SPECT: a monte carlo study. Acta Oncol. 2011;50:981–989.
   PubMed Web of Science ®Google Scholar
• Sandstrom M, Ilan E, Karlberg A, et al. Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours. EJNMMI Phys. 2015;2:24.
   PubMed Web of Science ®Google Scholar
• Sandstrom M, Garske-Roman U, Granberg D, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54:33–41.
   PubMed Web of Science ®Google Scholar
• Sandstrom M, Garske U, Granberg D, et al. Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol Imaging. 2010;37:212–225.
   PubMed Web of Science ®Google Scholar
• Garske U, Sandstrom M, Johansson S, et al. Minor changes in effective half-life during fractionated 177Lu-octreotate therapy. Acta Oncol. 2012;51:86–96.
   PubMed Web of Science ®Google Scholar
• Fleming JS. A technique for the absolute measurement of activity using a gamma camera and computer. Phys Med Biol. 1979;24:176–180.
   PubMed Web of Science ®Google Scholar
• Thames HD, Ang KK, Stewart FA, et al. Does incomplete repair explain the apparent failure of the basic LQ model to predict spinal cord and kidney responses to low doses per fraction? Int J Radiat Biol. 1988;54:13–19.
   PubMed Web of Science ®Google Scholar
• Prasad V, Bodei L, Kidd M, et al. Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an einsteinian view of the facts and myths. Eur J Nucl Med Mol Imaging. 2014;41:1825–1830.
   PubMed Web of Science ®Google Scholar
• Cremonesi M, Botta F, Di Dia A, et al. Dosimetry for treatment with radiolabelled somatostatin analogues. A review. Q J Nucl Med Mol Imaging. 2010;54:37–51.
   PubMed Web of Science ®Google Scholar
• Garkavij M, Nickel M, Sjogreen-Gleisner K, et al. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010;116:1084–1092.
   PubMed Web of Science ®Google Scholar
• Wehrmann C, Senftleben S, Zachert C, et al. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm. 2007;22:406–416.
   PubMed Web of Science ®Google Scholar